Patient P-02185

Synthetic patientMETA-24 · Day 171 · 65–74 · F · baseline S14Steering view · 3D Open companion preview

Therapy response

Improving

Tolerance

Unstable

GI state

Stable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

73%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 68 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 77 GI-04 recommended — GI Support Protocol GI-04
Day 78 Patient accepted — Started GI-04 in the companion
Day 78 ME-01 recommended — Monitoring Escalation ME-01
Day 79 Patient accepted — Started ME-01 in the companion
Day 82 Deterioration detected before clinical escalation — Monitoring Escalation ME-01
Day 86 GI symptom burden −33% vs expected — GI Support Protocol GI-04
Day 92 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 68.

Primary contributors, last 14 days

Inflammatory activity+13
Toxicity+9
Nutritional resilience-7
GI instability+2
Treatment adherence-2

What helped?

GI Support Protocol GI-04Day 77
Result: symptom burden −33%
Monitoring Escalation ME-01Day 78
Result: deterioration detected before clinical escalation

LIFE OS recommendation

Supportive Compound SC-12

63%

probability of meaningful tolerance improvement

284 similar trajectories
69% showed improvement
median effect visible after 6 days

Daily trackers

Molecule settings

The trackers this program marks as important, last 14 days vs the 14 before.

Active minutes

Wearable

7 min

worsening · -15.4 vs previous 14 d

Sleep duration

Wearable

6.5 h

stable · -0.0 vs previous 14 d

Energy level

Daily log

3.4/10

worsening · -0.9 vs previous 14 d

Steps

Wearable

1,471

worsening · -1,302 vs previous 14 d

GI burden

Companion

52.2/100

worsening · +9.5 vs previous 14 d

Adherence

Companion

53.1 %

stable · +0.3 vs previous 14 d

Sleep quality

Wearable

29/100

worsening · -4.7 vs previous 14 d

Glucose, CGM daily mean

CGM

149 mg/dL

stable · +2.8 vs previous 14 d

This trajectory is decaying — what would help, what would not

Steering view →

Heading towards restoration · 30 from the failing basin, 61 from restoration.

Would help

NP-02 Dietary Support Protocol
59% improved among 32 similar · onset 10 d · confidence 73%
SC-12 Supportive Compound
69% improved among 26 similar · onset 6 d · confidence 73%
CR-01 Clinician Review
100% improved among 6 similar · onset 5 d · confidence 73%
More protein
GI -4.4 next day on high-intake days · n 20

Would not help

Keep fat low
GI +4.5 next day on high-intake days · n 15
Keep histamine low
GI +3.4 next day on high-intake days · n 21
Keep fibre low
GI +2.7 next day on high-intake days · n 20

State influencers · digestive

Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

Dietary fat load
+4.5detractor · 95%
Protein
-4.4supporter · 95%
Histamine load
+3.4detractor · 95%
Insoluble fibre
+2.7detractor · 87%
Ultra-processed food
-1.5no signal · 38%
Simple carbohydrates
-1.1no signal · 29%
Alcohol
-0.8no signal · 21%
Caffeine
+0.6no signal · 15%

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 29/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Inflammatory signalling ↑60
- MicrobiomeBacteroides fragilis expansion
- BloodInflammatory load index 65
- WearableHRV 25 ms, trending down
Mucosal barrier integrity ↓50
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 52 and rising
Drug metabolism and exposure ↑20
- BloodToxicity index 59
Autonomic recovery ↓20
- Wearable1,471 steps/day

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure

Microbiome

Shannon diversity 3 · butyrate capacity 29/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisHigh
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 27 ms
Sleep: 6.5 h
Steps: 1,256
Resting HR: 73 bpm

Daily log: GI score 52, nutritional resilience 38, adherence 53.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Keep the sleep window steady
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02159	53%	S14	GI-04	improved	47
P-02125	52%	S14	GI-04	improved	55
P-02648	50%	S14	SC-12	improved	47
P-02363	49%	S14	GI-04	improved	49
P-02445	47%	S09	GI-04	improved	43
P-02106	46%	S14	GI-04	improved	44
P-02149	46%	S14	GI-04	improved	50
P-02633	46%	S14	NP-02	improved	48
P-02643	46%	S14	SC-12	improved	46
P-02002	45%	S14	GI-04	improved	47
P-02574	45%	S14	ME-01	improved	45
P-02094	44%	S14	NP-02	improved	53